Unknown

Dataset Information

0

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.


ABSTRACT: Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging. Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64-839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9-10%. The other 16 patients (88.9%) had tumor volume reductions of 2-69%. Six patients (33.3%) had tumor volume reductions ?50%. Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted.

SUBMITTER: Kim SY 

PROVIDER: S-EPMC7492269 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.

Kim Soo Young SY   Kim Seok-Mo SM   Kim Jun Won JW   Lee Ik Jae IJ   Jeon Tae Joo TJ   Chang Hojin H   Kim Bup-Woo BW   Lee Yong Sang YS   Chang Hang-Seok HS   Park Cheong Soo CS  

Frontiers in endocrinology 20200902


<b>Background:</b> Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. <b>Methods:</b> This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received  ...[more]

Similar Datasets

| S-EPMC5331066 | biostudies-literature
| S-EPMC8011355 | biostudies-literature
| S-EPMC8131394 | biostudies-literature
| S-EPMC6556325 | biostudies-literature
| S-EPMC5079697 | biostudies-literature
| S-EPMC8586669 | biostudies-literature
| S-EPMC7922355 | biostudies-literature
| S-EPMC8290324 | biostudies-literature
| S-EPMC9279913 | biostudies-literature
| S-EPMC6982268 | biostudies-literature